Sanofi, Formation Bio, and OpenAI Team Up to Revolutionize Drug Development with AI

Sanofi, Formation Bio, and OpenAI have announced a groundbreaking collaboration to accelerate drug development through advanced AI-powered software. This partnership aims to streamline the drug development process, making it more efficient and effective, and ultimately bringing new medicines to patients faster.

Sanofi, one of the world's leading biopharmaceutical companies, will leverage its proprietary data to develop AI models in partnership with OpenAI and Formation Bio. This collaboration marks a significant milestone in Sanofi’s journey to become the first biopharma company powered by AI at scale.

Paul Hudson, CEO of Sanofi, emphasized the transformative potential of this partnership: "This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its-kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments."

OpenAI, a global leader in AI technology, will provide cutting-edge AI capabilities, including fine-tuning models and offering deep AI expertise. The company will contribute dedicated resources and thought partnership to ensure the successful integration and application of AI technologies in drug development.